Table 2. Comparison between responders and non-responders.
| Factor | Responder(n = 9) | Non-responder(n = 18) | P Value |
|---|---|---|---|
| At time of LT | |||
| Age (years) | 46.0 (36–60) | 47.5 (26–64) | 1.000 |
| Etiology (with cirrhosis) | 8 (88.89%) | 12 (66.67%) | 0.336 |
| Positive HBsAg | 7 (77.78%) | 16 (88.89%) | 0.582 |
| Positive HBV DNA | 6 (66.67%) | 7 (38.89%) | 0.236 |
| MELD score | 19 (3–24) | 24 (3–26) | 0.803 |
| HBV history (years) | 8 (3–23) | 11.5 (1–23) | 0.860 |
| Interval since LT (>600 days) | 9 (100.00%) | 11 (61.11%) | 0.059 |
| At time of enrollment | |||
| Age (years) | 48.0 (38–62) | 51.5 (27–67) | 0.781 |
| BMI (kg/m2) | 23.72±2.93 | 24.06±3.01 | 0.782 |
| Anti-HBs (IU/L) | 19.87(0.10–45.84) | 15.20(0.00–53.76) | 1.000 |
| Serum creatinine (umol/L) | 91±17 | 90±15 | 0.875 |
| WBC(*10^9/L) | 5.62±1.17 | 5.83±1.46 | 0.703 |
| NEUT% | 60.83±7.51 | 55.42±8.86 | 0.129 |
| LY% | 27.09±6.40 | 33.01±10.22 | 0.126 |
| MO% | 7.37±2.18 | 7.56±2.54 | 0.846 |
| EO% | 4.36±4.40 | 3.61±5.19 | 0.714 |
| BASO% | 0.34±0.12 | 0.42±0.19 | 0.316 |
| LY/EO (≤15) | 8 (88.89%) | 7 (38.89%) | 0.019 |
| During vaccination | |||
| Smoking | 2 (22.22%) | 3 (16.67%) | 1.000 |
| HBIG administration(>6 times) | 2 (22.22%) | 4 (22.22%) | 1.000 |
| Single immunosuppression | 3 (33.33%) | 5 (27.78%) | 1.000 |
| Concentration of TC(ug/L) | 6.44±2.94 | 5.79±2.17 | 0.560† |
| NAs (LAM/ADV/ETV) | 2/3/4 | 5/3/10 | 0.617 |
†Data were missing in five cases due to their single immunosuppression regimen.
MELD, model for end-stage liver disease; BMI, body mass index; WBC, white blood cell; NEUT, neutrophil; LY, lymphocyte; MO, monocyte; EO, eosinophil; BASO, basophil; TC, tacrolimus; LAM, lamivudine; ADV, adefovir dipivoxyl; ETV, entecavir.